Dr. Oskar Smrzka

Biography

Oskar Smrzka leads AFFiRiS’ Enabling Technologies Department in charge of establishing new molecular targeting concepts and of validating preclinical vaccine candidates. His Lab contributes to setting up functional screenings and establishing in vivo models for the preclinical active immunotherapies pipeline of AFFiRiS. Before joining the company, Dr. Smrzka started his career at the Vienna Medical University followed by training as molecular biologist at the Research Institute of Molecular Pathology (Vienna IMP). After his PostDoc years in Amsterdam (The Netherlands Cancer Institute; epigenetics) and Paris (Institut Curie; cell biology), he joined the St. Anna Children’s Cancer Research Institute (CCRI, Vienna), addressing fundamental topics in molecular cell biology of rare childhood tumors. Entering biotech industry, he established a functional small molecule screening pipeline for a start-up biotech company at the Vienna Biocenter. At AFFiRiS, Dr. Oskar Smrzka’s Enabling Technologies group is currently focusing on preclinical validation and development of therapeutic active immunotherapies for Huntington’s disease and allergy.

Research Interest

currently focusing on preclinical validation and development of therapeutic active immunotherapies for Huntington’s disease and allergy.